TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29374733
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) analgesia - single-dose
Study: 29374733
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) analgesia - repeated-dose
Study: 29374733
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) analgesia - continuous infusion
Study: 25223547
Drug: One-day bowel
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day bowel preparation with Miralax®
Study: 25223547
Drug: Three-day bowel
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day bowel preparation with Miralax®
Study: 11007446
Drug: diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphenhydramine 50 mg-8 hr TIB
Study: 8436497
Drug: Trazodone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (1 mg/kg a day divided into 3 doses) for 12 weeks
Study: 29278443
Drug: Solution-focused approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused approach interview technique (8 interviews at 2-week intervals, 30-45 min each)
Study: 29278443
Drug: Solution-focused approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused approach interview technique
Study: 16579997
Drug: CC+MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+MET
Study: 9391292
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg three times daily
Study: 7505523
Drug: Continuous diluted
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous diluted intravesical instillation of bleomycin (120 mg/2,000 ml saline solution/day for 3 days), instillation BCG (40 mg/40 ml saline solution/weekly 6 times), and UFT (400 mg orally/day for 2 years maximum)
Study: 3569448
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg ambroxol daily
Study: 20232195
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (adequate analgesia, osteoporosis medication, individualized physiotherapy or braces)
Study: 12211220
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy in postmenopausal women
Study: 12211220
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy to reduce cardiovascular risk
Study: 23878167
Drug: IFX dose
Normalized name: IFx-Hu2.0
DrugBank: IFx-Hu2.0 (DB18396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFX dose intensification (5 mg/kg every 4 weeks)
Study: 23878167
Drug: Interventions based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions based on serum IFX and IFX antibody levels using the proposed algorithm
Study: 16285179
Drug: Autologous tumour
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumour cell vaccine (n = 9)
Study: 9084515
Drug: 0.5% interpleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% interpleural bupivacaine (10 ml)
Study: 1912105
Drug: m-CPP (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (up to 80 mg/day for 16 days)
Study: 29432379
Drug: Dexmedetomidine 1 μg kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.4 μg kg h
Study: 29432379
Drug: Dexmedetomidine 1 μg kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.6 μg kg h
Study: 29432379
Drug: Dexmedetomidine 0.6 μg kg h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg kg h
Study: 29432379
Drug: Dexmedetomidine 0.4 μg kg h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg kg h
Study: 26766541
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target international normalized ratio, 2‐3)
Study: 25516016
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen three times a day for three days
Study: 25516016
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mecillinam three times a day for three days
Study: 23649063
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing 6% potassium nitrate and 0.11% fluoride ions
Study: 23782487
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) administration
Study: 20970637
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose solution)
Study: 18489783
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily for 12 weeks (Group I)
Study: 18489783
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily for 12 weeks (Group II)
Study: 15634273
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 50 mg twice daily
Study: 21438804
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg twice daily
Study: 15634273
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 300 mg once daily
Study: 15634273
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 225 mg twice daily
Study: 16036023
Drug: Ventricular assist
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular assist devices as destination therapy
Study: 10996579
Drug: Bacterial load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial load of 10(6) to 10(7) CFU/mL
Study: 10996579
Drug: Bacterial load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial load of 10(7) to 10(8) CFU/mL
Study: 10996579
Drug: Bacterial load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial load of 10(8) or greater CFU/mL
Study: 9115022
Drug: Bronchodilator drugs
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator drugs
Study: 3546151
Drug: Ofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (100 mg, b.i.d. for 7 days)
Study: 3546151
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg, b.i.d. for 7 days)
Study: 24880581
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing therapy (n=10)
Study: 24880581
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n=10)
Study: 20424140
Drug: Lipid heparin
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid heparin infusion (LHI) inducing physiological elevations of FFAs
Study: 20424140
Drug: Discontinued insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued insulin infusion
Study: 20424140
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin supply
Study: 18793446
Drug: Physiotherapist-delivered OA
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-delivered OA education control treatment (8 individual sessions over 12 weeks)
Study: 16182685
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements
Study: 21336185
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SMI)
Study: 6510453
Drug: Penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (40 mg)
Study: 159057
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (30 mg)
Study: 29771596
Drug: ExPEC4V vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPEC4V vaccine (4, 8, and 16 µg PS/serotype)
Study: 21998259
Drug: AHR strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHR strategy (titrating inhaled corticosteroid against mannitol PD(10))
Study: 20480225
Drug: Celecoxib 800
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 800 mg/day during cycles 5-8
Study: 20480225
Drug: Trastuzumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (8 mg/kg then 6 mg/kg IV every 3 weeks)
Study: 20480225
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (control for HER2-negative)
Study: 20480225
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional preoperative treatment (control for HER2-positive)
Study: 18705755
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Nigella sativa seed extract twice a day
Study: 18705755
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Nigella sativa seed extract twice a day
Study: 15744449
Drug: 25-hydroxy vitamin
Normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxy vitamin D levels below 20 ng/ml
Study: 15744449
Drug: 25-hydroxy vitamin
Normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxy vitamin D levels below 30 ng/ml
Study: 14710908
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of isotonic saline (placebo)
Study: 10070048
Drug: Mild hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hyperglycemia (approximately 10 mmol/l)
Study: 10070048
Drug: Euglycemia (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (approximately 4 mmol/l)
Study: 7668024
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin q.i.d.
Study: 7668024
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin i.v. (single dose)
Study: 2107773
Drug: EMLA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA and glyceryl trinitrate ointment
Study: 7468946
Drug: Nebulized racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized racemic epinephrine (Micronephrine) at a dose of 0.9 mg/kg body-weight
Study: 7468946
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol at a dose of 0.15 mg/kg body-weight
Study: 3771813
Drug: Propranolol 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 640 mg/day
Study: 31083192
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN) combined with usual care (UC) for 4 weeks
Study: 23094314
Drug: Calcipotriene ointment
Normalized name: Calcipotriene Ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene ointment 0.005% applied twice daily
Study: 15153904
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment 0.1% applied twice daily
Study: 23094314
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcipotriene and tacrolimus (morning calcipotriene and evening tacrolimus)
Study: 18007570
Drug: Guideline concordant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline concordant treatments for mixed episodes
Study: 18007570
Drug: Guideline concordant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline concordant treatments for hypomanic/manic episodes
Study: 18007570
Drug: Guideline concordant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline concordant treatments for depressive episodes
Study: 12010266
Drug: Ketorolac 20
Normalized name: ketorolac 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 20 mg intravenously in the non-operative arm before surgery (systemic presurgery group)
Study: 12010266
Drug: Ketorolac 20
Normalized name: ketorolac 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 20 mg intravenously to the operative arm after tourniquet inflation (regional presurgery group)
Study: 12010266
Drug: Ketorolac 20
Normalized name: ketorolac 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 20 mg intravenously in the non-operative arm after surgery (systemic postsurgery group)
Study: 31099864
Drug: Payments from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Payments from pharmaceutical companies
Study: 25856243
Drug: Standard biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard biofeedback protocol plus daily home use of a Peritron perineometer (intervention)
Study: 23419231
Drug: Quetiapine 400
Normalized name: quetiapine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 400 mg/d
Study: 22379909
Drug: Isobaric bypivacain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bypivacain (5 mg/ml)
Study: 22379909
Drug: Ropivacain (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacain (5 mg/ml)
Study: 15210591
Drug: Anemia (Hb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (Hb < or =12.0 g/dL)
Study: 15210591
Drug: Higher baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher baseline hemoglobin (1 g/dL increase)
Study: 8615506
Drug: Lansoprazole-lansoprazole (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole-lansoprazole (Group L-L)
Study: 8615506
Drug: Lansoprazole-placebo (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole-placebo (Group L-P)
Study: 8615506
Drug: Placebo-lansoprazole (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-lansoprazole (Group P-L)
Study: 4009215
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiation treatment (RTIF)
Study: 4009215
Drug: Extended field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended field radiation treatment (RTEF)
Study: 30286238
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioral therapy for 8 weeks
Study: 30286238
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioral therapy
Study: 28003203
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (0-820 mg) with methylxanthines (0-220 mg)
Study: 28003203
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (0-820 mg)
Study: 26408732
Drug: Directly stopped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly stopped VEGFR TKI treatment
Study: 26408732
Drug: Continued VEGFR
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued VEGFR TKI treatment for another two weeks
Study: 24047919
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg Ca/d
Study: 18205185
Drug: Immediate-start zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate-start zoledronic acid (4 mg intravenously biannually for 5 years)
Study: 18205185
Drug: Delayed-start zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed-start zoledronic acid (4 mg intravenously biannually for 5 years)
Study: 18192897
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg/day)
Study: 14519799
Drug: Rectal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal infusion of acetate (60 mmol/L), propionate (20 mmol/L), and butyrate (20 mmol/L)
Study: 14519799
Drug: Butyrate-containing infusions
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate-containing infusions
Study: 14519799
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of three SCFA
Study: 11097191
Drug: Treatment readiness
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment readiness training
Study: 1417159
Drug: two annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: two annual doses of ivermectin 100 mcg/kg
Study: 1417159
Drug: three semi‐annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: three semi‐annual doses of ivermectin 100 mcg/kg
Study: 1417159
Drug: two annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: two annual doses of diethylcarbamazine (DEC) 3 mg/kg
Study: 1417159
Drug: three semi‐annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: three semi‐annual doses of diethylcarbamazine (DEC) 3 mg/kg
Study: 1417159
Drug: two annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: two annual doses of diethylcarbamazine (DEC) 6 mg/kg
Study: 4074419
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg bencyclane intravenously
Study: 4074419
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg bencyclane intravenously
Study: 4074419
Drug: 71 mg
Normalized name: nilotinib 71 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 71 mg bencyclane orally as a solution in water
Study: 4074419
Drug: 143 mg
Normalized name: ferrous sulfate 143 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 143 mg bencyclane orally as a solution in water
Study: 4074419
Drug: Intravenous bencyclane
Normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bencyclane
Study: 19281922
Drug: Rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin therapy
Study: 18408611
Drug: CAF-5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-5 (5 mg.kg(‐1))
Study: 18408611
Drug: CAF-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-3 (3 mg.kg(‐1))
Study: 18408611
Drug: CAF-1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-1 (1 mg.kg(‐1))
Study: 8433469
Drug: Air suspension
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air suspension bed
Study: 2890423
Drug: ZK 91
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 91 296 and ZK 95 962 (high doses, intravenous)
Study: 2890423
Drug: ZK 93
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93 426 in combination with lormetazepam
Study: 23569138
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet with keto acid supplementation (0.1 g/kg IBW per day)
Study: 19214941
Drug: BGP-15 200
Normalized name: Bgp-15 free base
DrugBank: NP-51 (DB16995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGP-15 200 mg
Study: 19214941
Drug: BGP-15 400
Normalized name: Bgp-15 free base
DrugBank: NP-51 (DB16995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGP-15 400 mg
Study: 17080881
Drug: Panavia F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panavia F 2.0 (P) at 20 g/mm²
Study: 17080881
Drug: Panavia F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panavia F 2.0 (P) at 40 g/mm²
Study: 17080881
Drug: RelyX Unicem
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RelyX Unicem (RU) at 20 g/mm²
Study: 17080881
Drug: RelyX Unicem
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RelyX Unicem (RU) at 40 g/mm²
Study: 17080881
Drug: Maxcem (M)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxcem (M) at 20 g/mm²
Study: 17080881
Drug: Maxcem (M)
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxcem (M) at 40 g/mm²
Study: 11712625
Drug: Citalopram (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (specific dosage not mentioned)
Study: 10487593
Drug: PGG-glucan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGG-glucan 0.5 mg/kg
Study: 10487593
Drug: PGG-glucan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGG-glucan 1.0 mg/kg
Study: 7639438
Drug: Slow-release sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it)
Study: 2654788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant interferon (rIFN) alpha‐2 and chemotherapy
Study: 2654788
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (VMCP)
Study: 19205
Drug: Tolmetin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (1.6 g daily)
Study: 19205
Drug: Alclofenac (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alclofenac (4 g daily)
Study: 31064847
Drug: AT1413 bispecific
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1413 bispecific T-cell-engaging antibody (bTCE)
Study: 23822797
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (25 μg/day as cholecalciferol tablets)
Study: 21219433
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of rapid-acting insulin (mean 7.3±0.2 units)
Study: 21219433
Drug: 75% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% dose of rapid-acting insulin (mean 5.4±0.1 units)